Literature DB >> 11085899

Dopa-induced blood flow responses in nonhuman primates.

T Hershey1, K J Black, J L Carl, J S Perlmutter.   

Abstract

Initially, treatment with the dopamine precursor levodopa provides substantial symptomatic relief for patients with Parkinson's disease (PD). However, as the disease progresses, side effects such as involuntary movements or psychosis may accompany the response to medication. The mechanisms underlying these actions of levodopa remain unclear. To develop methodology for longitudinal studies of the effects of PD and levodopa treatment in living nonhuman primates, we first studied the effects of an acute dose of levodopa on regional brain activity in sedated baboons using positron emission tomography. We found that levodopa significantly decreased regional cerebral blood flow (rCBF) bilaterally in putamen and right cingulate and increased rCBF in right lateral temporal cortex and bilateral frontal cortex. We then performed similar studies on a nemestrina in awake and sedated states to determine whether these responses were affected by sedation. Interestingly, the directions of the rCBF responses in the putamen and temporal cortex were reversed depending on the presence or absence of sedation. Specifically, responses were decreased in sedated animals, but increased dose-dependently in the awake nemestrina. These findings have important implications for the interpretation of studies that use anesthesia. The responses in the awake nemestrina were most similar to those reported in humans and thus may be the most useful model system. Future imaging studies using selective dopaminergic agents in awake animals may permit the identification of relatively specific agonist-mediated pathways and may help separate the mechanisms that mediate levodopa's benefit from those that produce its unwanted side effects. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11085899     DOI: 10.1006/exnr.2000.7522

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  16 in total

1.  Network modulation in the treatment of Parkinson's disease.

Authors:  Kotaro Asanuma; Chengke Tang; Yilong Ma; Vijay Dhawan; Paul Mattis; Christine Edwards; Michael G Kaplitt; Andrew Feigin; David Eidelberg
Journal:  Brain       Date:  2006-07-14       Impact factor: 13.501

2.  A possible substrate for dopamine-related changes in mood and behavior: prefrontal and limbic effects of a D3-preferring dopamine agonist.

Authors:  Kevin J Black; Tamara Hershey; Jonathan M Koller; Tom O Videen; Mark A Mintun; Joseph L Price; Joel S Perlmutter
Journal:  Proc Natl Acad Sci U S A       Date:  2002-12-13       Impact factor: 11.205

3.  Dopamine effects on frontal cortical blood flow and motor inhibition in Parkinson's disease.

Authors:  Paula Trujillo; Nelleke C van Wouwe; Ya-Chen Lin; Adam J Stark; Kalen J Petersen; Hakmook Kang; David H Zald; Manus J Donahue; Daniel O Claassen
Journal:  Cortex       Date:  2019-01-29       Impact factor: 4.027

4.  Mesocorticolimbic hemodynamic response in Parkinson's disease patients with compulsive behaviors.

Authors:  Daniel O Claassen; Adam J Stark; Charis A Spears; Kalen J Petersen; Nelleke C van Wouwe; Robert M Kessler; David H Zald; Manus J Donahue
Journal:  Mov Disord       Date:  2017-06-19       Impact factor: 10.338

5.  Postprandial plasma PYY concentrations are associated with increased regional gray matter volume and rCBF declines in caudate nuclei--a combined MRI and H2(15)O PET study.

Authors:  Christopher M Weise; Pradeep Thiyyagura; Eric M Reiman; Kewei Chen; Jonathan Krakoff
Journal:  Neuroimage       Date:  2011-12-21       Impact factor: 6.556

6.  Quantification of indirect pathway inhibition by the adenosine A2a antagonist SYN115 in Parkinson disease.

Authors:  Kevin J Black; Jonathan M Koller; Meghan C Campbell; Debra A Gusnard; Stephen I Bandak
Journal:  J Neurosci       Date:  2010-12-01       Impact factor: 6.167

7.  Long term treatment and disease severity change brain responses to levodopa in Parkinson's disease.

Authors:  T Hershey; K J Black; J L Carl; L McGee-Minnich; A Z Snyder; J S Perlmutter
Journal:  J Neurol Neurosurg Psychiatry       Date:  2003-07       Impact factor: 10.154

8.  Distributed neural actions of anti-parkinsonian therapies as revealed by PET.

Authors:  I K Goerendt; A D Lawrence; M A Mehta; J S Stern; P Odin; D J Brooks
Journal:  J Neural Transm (Vienna)       Date:  2005-07-29       Impact factor: 3.575

9.  Levodopa effects on [ (11)C]raclopride binding in the resting human brain.

Authors:  Kevin J Black; Marilyn L Piccirillo; Jonathan M Koller; Tiffany Hseih; Lei Wang; Mark A Mintun
Journal:  F1000Res       Date:  2015-01-23

10.  Rapid quantitative pharmacodynamic imaging by a novel method: theory, simulation testing and proof of principle.

Authors:  Kevin J Black; Jonathan M Koller; Brad D Miller
Journal:  PeerJ       Date:  2013-08-01       Impact factor: 2.984

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.